Provided in combination with cetuximab, a novel EGFR–resistance-mutation selective allosteric inhibitor (EAI045) has been observed to be effective in a mouse model of NSCLC harboring EGFRL858R/T790M/C797S. This evidence concerns the gene EGFR and non-small cell lung carcinoma.